The Wegovy Step-Up Approach: How the Dose Trial Works in Practice

Why does Wegovy use a step-up schedule rather than starting at full dose?

Semaglutide slows the movement of food through the stomach and reduces appetite by acting on GLP-1 receptors in the brain and gut. Both of those effects are dose-dependent, which means the higher the dose, the stronger the signal. Starting at the full 2.4 mg maintenance dose in week one would almost certainly mean a rough first month for most people, the stomach takes time to adapt to a slower rate of gastric emptying.

The step-up schedule manages that adjustment deliberately. The 0.25 mg starting dose is low enough that most people experience only mild, if any, side effects, and the four-week intervals give the body a chance to settle before the dose climbs again. The NHS medicines information for semaglutide notes that nausea, vomiting, diarrhoea and constipation are the most commonly reported effects, and that they tend to be most noticeable after starting or increasing a dose, often easing within days to a couple of weeks. Climbing gradually keeps those effects manageable for most people rather than overwhelming.

It is also worth knowing that the 0.25 mg and 0.5 mg doses are not where the weight-loss effect is strongest. They are part of the journey to maintenance, not the destination. If you are early in the schedule and feeling impatient, that is entirely understandable, but our guide to Wegovy step-up dosing explains why the pace is intentional and what to expect as each increase approaches. Our page on how Wegovy's dose steps are structured has more on what changes at each level.

What exactly does each step of the trial look like?

The licensed UK schedule for Wegovy injection runs as follows: 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then 1.0 mg for four weeks, then 1.7 mg for four weeks, before arriving at the 2.4 mg maintenance dose. That is a minimum of 16 weeks from first injection to full dose, though in practice many people spend longer at one or more steps if they are still experiencing side effects or their prescriber considers it clinically appropriate to hold steady.

In January 2026, the MHRA approved a higher 7.2 mg maintenance dose (initially available via three 2.4 mg pens weekly, and from April 2026, as a dedicated single-dose 7.2 mg pen) for adults with a BMI of 30 or above. The starting point and titration pathway remain the same; 7.2 mg is simply a higher ceiling that some patients may eventually reach under clinical supervision. More detail on the full range of available strengths is on our guide to Wegovy dose options.

What the schedule does not do is run like a fixed timer. A prescriber assesses how each person is tolerating treatment before confirming the next step. If four weeks at 1.0 mg has left someone still battling nausea, staying there a little longer is not a setback, it is the system working as intended. The NICE recommendation for semaglutide (TA875) sits within a framework that emphasises clinical oversight at each stage, not a one-size-fits-all calendar. You can read NICE's published guidance at nice.org.uk/guidance/ta875.

Can I skip a step or move through the schedule faster?

The short answer is: only your prescriber can make that call, and they will want good reason to. The step-up schedule is not arbitrary bureaucracy, it reflects what the clinical trial programme found about tolerability across thousands of participants. Moving ahead of schedule increases the risk of side effects that are unpleasant enough to cause people to stop treatment altogether, which defeats the purpose.

That said, there are real situations where clinical judgment leads to a different pace. People transferring from a higher dose of semaglutide, for instance, would not normally restart at 0.25 mg. A full review of your treatment history and current dose is part of what a prescriber needs before confirming any step. This is one reason why stepping up on Wegovy should always happen with a clinician in the loop rather than based on a schedule found online.

Timing matters in practical terms too. If a dose increase falls during a busy period (a work trip, a bank holiday, a week where you know eating will be unpredictable) it is worth flagging that to your prescriber in advance. There is no rigid rule that says you must increase on a particular Monday, but changes should not happen in isolation either.

One question our prescribers hear regularly is what to do if a dose feels right and weight loss is progressing well at a lower maintenance level. The honest answer is that the evidence base for weight loss, including the STEP 1 trial published in the New England Journal of Medicine, is strongest at the 2.4 mg dose, but clinical decisions are individual. A prescriber can assess whether staying at a lower dose is appropriate for a given person. Our page on how high Wegovy doses can go covers the evidence at each level in more detail.

What happens if the step-up causes side effects that feel unmanageable?

Gastrointestinal effects are common during titration, nausea especially, but also loose stools, constipation, acid reflux and reduced appetite to the point of eating very little. For most people, these are temporary. Eating smaller meals, avoiding fatty or heavily spiced food, and not lying down straight after eating can all help. Staying hydrated matters, particularly if vomiting or diarrhoea is a feature, because dehydration can become a concern in its own right.

There are symptoms that go beyond ordinary titration discomfort and need prompt medical attention. Severe, persistent stomach pain that spreads to the back (with or without vomiting) should be assessed urgently, as this can be a sign of pancreatitis. Allergic reactions, sudden vision changes, signs of dehydration, and significant low mood should also be taken seriously and not waited out. The MHRA's Yellow Card service allows patients to report suspected side effects directly, and is worth bookmarking.

If side effects are making the current dose difficult to sustain, the right move is to contact your prescriber rather than stopping abruptly or reducing the dose on your own. Holding steady at the current level, or occasionally stepping back, are options a clinician can discuss, but those are clinical decisions, not self-managed ones. Our team at nume contact is available seven days a week for aftercare support.

For a broader overview of what semaglutide treatment involves from the beginning, our Wegovy treatment guide covers the medicine, eligibility and how to access it through a regulated private prescriber in the UK. If you are ready to explore whether treatment is right for you, you can start your free consultation with our GPhC-registered prescribers today.